MedTrace Logo

Dose Escalation and Expansion Study of CPO102, an Anti-claudin 18.2 ADC in Patients With Advanced Cancers

NCT05043987 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2023-09-07

No results posted yet for this study

Summary

This Phase 1 study will be a multicenter, single agent, dose escalation and dose expansion study conducted in patients with advanced late stage cancer (pancreatic or gastric including esophageal junction cancers) for which the investigator determines there to be no other standard of care or higher priority therapies available.

Conditions

Interventions

DRUG

CPO102

Anti-claudin 18.2 Antibody-MMAE Drug Conjugate

Sponsors & Collaborators

  • CSPC Megalith Biopharmaceutical Co.,Ltd.

    collaborator INDUSTRY

  • Conjupro Biotherapeutics, Inc.

    lead INDUSTRY

Principal Investigators

  • Jiangfeng Su, MD, PhD · Conjupro Biotherapeutics, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-11-16
Primary Completion
2022-11-16
Completion
2022-11-16
FDA Drug
Yes

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05043987 on ClinicalTrials.gov